By Gabriel Paijo 
In a clinical study that bridges the gap between nutritional science and epigenetic oncology, researchers have unveiled findings from the EVITA trial, a Phase 2 investigation exploring the impact of oral Vitamin C supplementation on individuals at high risk for blood cancers. Published in the peer-reviewed journal CANCER, a publication of the American Cancer Society, the study provides a nuanced look at how a common dietary supplement might influence the biological trajectory of myeloid malignancies. While the primary objective regarding the growth rate of precancerous cells did not show a significant divergence between the treatment and placebo groups, the secondary exploratory findings regarding overall survival and inflammatory markers have sparked considerable interest within the hematological research community.
The foundation of this research lies in the intricate relationship between Vitamin C (ascorbic acid) and cellular proteins known as TET (Ten-eleven translocation) enzymes. These enzymes play a critical role in the epigenetic regulation of the genome, specifically by facilitating DNA demethylation—a process that determines whether certain genes are expressed or silenced. In many forms of blood cancer, particularly those involving the myeloid lineage, TET enzyme activity is significantly diminished, often due to genetic mutations. This reduction in activity leads to aberrant DNA methylation patterns, which can drive the transformation of healthy blood cells into malignant ones. By increasing the activity of these enzymes, researchers hypothesized that Vitamin C might serve as a corrective agent, restoring a more normal epigenetic landscape and potentially slowing the progression of the disease.
The Design and Methodology of the EVITA Trial
The EVITA trial—a randomized, double-blind, placebo-controlled study—was conducted across multiple sites in Denmark and the United States, representing a collaborative effort between Rigshospitalet at Copenhagen University Hospital and the Van Andel Institute. The trial enrolled 109 participants, all of whom were diagnosed with either a low-risk form of blood cancer or a precursor condition with a high potential for malignant transformation. These conditions include Myelodysplastic Syndromes (MDS) and Clonal Hematopoiesis of Indeterminate Potential (CHIP), both of which are characterized by the expansion of mutated blood cell clones.
Participants were divided into two nearly equal cohorts: 55 individuals were assigned to receive a daily oral dose of 1,000 mg of Vitamin C, while 54 individuals received a daily placebo. The treatment duration was set at 12 months, during which researchers closely monitored blood counts, bone marrow samples, and various biomarkers of inflammation and epigenetic activity. The choice of 1,000 mg as the daily dose was significant, as it represents a level far higher than the standard recommended dietary allowance (RDA) but remains within the safety profile for long-term oral consumption.
Analyzing the Survival Signal and Secondary Findings
The primary endpoint of the trial focused on whether Vitamin C supplementation could measurably reduce the proliferation rate of precancerous or cancerous cells. Upon analysis of the 12-month data, the researchers found that the growth rates of these cell populations were largely similar between the Vitamin C and placebo groups. This result suggested that, at the tested dosage and duration, Vitamin C did not directly halt the expansion of the abnormal clones in a way that was statistically distinguishable from the placebo.
However, as the study moved into its follow-up phase, a more complex picture began to emerge. At a median follow-up of 33.6 months—nearly three years after the initiation of the study—the researchers conducted an exploratory analysis of the intention-to-treat population. The data revealed a striking discrepancy in mortality rates: 35 participants had died during the follow-up period. Of these deaths, 24 occurred in the placebo group, while only 11 occurred in the group receiving Vitamin C.
This survival signal, while categorized as exploratory and requiring further validation, suggests that the benefits of Vitamin C may manifest not through the direct elimination of cancer cells, but through systemic improvements in the patient’s health and immune environment. Specifically, the Vitamin C group exhibited notable changes in inflammatory signaling. Chronic inflammation is a well-known driver of cancer progression and is often elevated in patients with myeloid disorders. The modulation of these inflammatory pathways aligns with better clinical outcomes and a reduced risk of secondary complications.
Clinical Observations and Side Effect Profiles
Beyond the survival data, the EVITA trial documented several clinical differences in the health status of the participants. Those in the Vitamin C cohort experienced fewer instances of several serious medical complications. Notably, there were reduced reports of:
- Anemia: A common and debilitating feature of blood disorders where the body lacks enough healthy red blood cells to carry adequate oxygen to tissues.
- Pneumonia: Respiratory infections are a leading cause of morbidity in patients with compromised bone marrow function.
- Internal Bleeding: Often caused by low platelet counts (thrombocytopenia), this was less frequent in the treatment group.
- Acute Aseptic Arthritis: A form of joint inflammation that appeared less frequently in those taking the supplement.
While these findings point toward a protective effect, the trial also identified specific side effects associated with the high-dose Vitamin C regimen. Gastrointestinal issues, including nausea and abdominal discomfort, were more prevalent in the Vitamin C group compared to the placebo group. These side effects are consistent with the known profile of high-dose oral ascorbic acid, which can act as an osmotic laxative in some individuals.
The Scientific Context: Epigenetics and "Cancer Interception"
The EVITA trial is a prominent example of the emerging field of "cancer interception"—a strategy that seeks to intervene in the early stages of carcinogenesis to prevent the development of full-blown malignancy. Unlike traditional oncology, which focuses on treating established tumors, interception targets the precursor states.
The role of Vitamin C in this context is deeply rooted in the work of the Van Andel Institute-Stand Up To Cancer (VAI-SU2C) Epigenetics Dream Team. For years, this collaborative group has investigated how epigenetic modifiers can be used to "reprogram" cancer cells. In the case of myeloid malignancies, the loss of TET2 enzyme function is a hallmark of the disease. Research in animal models and cell lines had previously shown that Vitamin C could mimic the effects of TET2 restoration, essentially forcing the cells to differentiate and behave more like healthy blood cells.
"The EVITA trial gives us a strong rationale to continue exploring if and how vitamin C might benefit people with certain pre-cancer or early-stage blood cancers," stated Dr. Peter A. Jones, co-senior author of the study and a leading figure at the Van Andel Institute. "More work is needed, but we are cautiously optimistic that these findings could inform future strategies to intercept leukemia development."
Chronology of Research and Institutional Support
The journey toward the EVITA trial results has been one of steady scientific progression:
- Initial Discovery (Early 2010s): Researchers identify the TET2 mutation as a frequent driver in myeloid cancers and discover that Vitamin C acts as a necessary cofactor for TET enzyme activity.
- Preclinical Validation (2015-2017): Laboratory studies demonstrate that Vitamin C supplementation can slow leukemia progression in mice with TET2 deficiencies.
- Trial Initiation (2018-2019): The EVITA trial is launched as a collaborative effort between US and Danish institutions, funded in part by the Stand Up To Cancer initiative.
- Data Collection (2019-2022): Participants undergo treatment and regular monitoring.
- Long-term Follow-up and Analysis (2023-2024): The survival signal is identified, leading to the current publication in CANCER.
The involvement of Rigshospitalet in Copenhagen adds a significant layer of clinical expertise. Dr. Kirsten Grønbæk, co-senior author and a member of the VAI-SU2C team, emphasized the necessity of moving toward larger-scale trials. "We are encouraged by our findings and what they ultimately could mean for people with these early-stage blood disorders," she said. "Although it is too soon to make recommendations based on our results, we are hopeful that a larger study will give us more definitive answers."
Implications for Future Treatment and the Path to Phase 3
Despite the encouraging survival data, the researchers and the American Cancer Society have issued a clear message: these results do not yet constitute a change in the standard of care. The survival benefit observed was an exploratory finding, meaning the study was not originally powered or designed specifically to prove a survival difference. In clinical research, such findings are viewed as "hypothesis-generating" rather than "confirmatory."
The next logical step is a Phase 3 clinical trial. A Phase 3 trial would involve hundreds, if not thousands, of participants and would be specifically designed to measure survival and the time to leukemia transformation as primary endpoints. Such a study would also allow for a more detailed analysis of which genetic subgroups—such as those with specific TET2 or IDH mutations—benefit most from Vitamin C.
Furthermore, the EVITA trial highlights the importance of distinguishing between different forms of Vitamin C administration. While this study utilized oral supplements, other research is investigating high-dose intravenous Vitamin C, which achieves much higher plasma concentrations and may have different pharmacological effects on cancer cells.
Broader Impact on Hematology
The implications of the EVITA trial extend beyond Vitamin C itself. It reinforces the importance of the "microenvironment" in blood cancers. By showing that a supplement can alter inflammatory signaling and potentially reduce non-cancer deaths (such as those from pneumonia or bleeding), the study suggests that supporting the overall health of the bone marrow environment is just as important as attacking the cancer clones themselves.
For patients currently living with CHIP or low-risk MDS, the study offers a glimmer of hope for a non-toxic, accessible intervention. However, medical professionals urge patients to consult with their oncologists before starting any high-dose supplement regimen, particularly given the gastrointestinal side effects and the potential for supplements to interfere with other medications.
As the scientific community awaits the development of a Phase 3 trial, the EVITA study stands as a significant milestone in epigenetic research. It validates the concept that targeting TET enzymes is a viable therapeutic avenue and provides the first clinical evidence in humans that Vitamin C may play a role in extending the lives of those at risk for some of the most challenging diseases of the blood. The transition from "nutritional supplement" to "epigenetic therapy" represents a new frontier in the fight against cancer, where the focus shifts from late-stage intervention to early-stage prevention and systemic health optimization.
